April 28, 2026

First Quarter 2026 Earnings Presentation

MIRION

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “strive”, “seeks”, “plans”, “would”, “will”, “understand” and similar words are intended to identify forward looking statements, but the absence of these words does not mean that a statement is not forward looking. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our backlog and order potential, our business strategy and plans, our objectives for future operations, macroeconomic trends including the trends in cancer care, nuclear power and small modular reactor industries, foreign exchange, interest rate and inflation expectations and any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions. There are a significant number of factors that could cause actual results to differ materially from statements made in this Presentation, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict in the Middle East, potential tariffs or other trade and supply chain disruptions, and risks of slowing economic growth or economic recession in the United States and globally; developments in the government budgets (defense and non-defense) in the United States (including the U.S.-Israel-Iran conflict) and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the government budget process, a U.S. government shutdown or the U.S. government’s failure to raise the debt ceiling; risks related to the public’s perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology system failures or other disruptions or cybersecurity, data security or other security threats; risks related to the implementation and enhancement of information systems; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures, investments and partnerships, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; risks related to the uncertainty of legal claims, litigation, arbitration and similar proceedings; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; and the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the United States Securities and Exchange Commission (the “SEC”) from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this Presentation are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe non-GAAP measures are useful in evaluating our operating performance, including organic revenues, adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted free cash flow, adjusted free cash flow conversion, net leverage. We use this non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. See the footnotes on the slides where these measures are discussed and the Non-GAAP reconciliations in the Appendix for a description of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures. Additionally, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control or cannot be reasonably predicted. Accordingly, a reconciliation for our guidance organic revenue growth, adjusted EBITDA, adjusted earnings per share, adjusted free cash flow, adjusted free cash flow conversion, and net leverage is not available without unreasonable effort.

Industry and Market Data

In this presentation, we rely on and refer to information and statistics regarding market participants in the sectors in which Mirion competes and other industry data. We obtained this information and statistics from third-party sources, including reports by market research firms and company filings. Mirion has not independently verified the data obtained from these sources and cannot assure you of the data’s accuracy or completeness.

Operating Metrics

This presentation contains certain operating metrics that our management uses to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions, including orders. See the Appendix to this presentation for our definitions of such metrics.

Mirion

Q1 Key Takeaways

Strong Q1 Orders and Backlog Growth

+19% Q1 orders growth excluding M&A[1]; +42% including M&A

$1.1B backlog; +19% excluding M&A; +38% including M&A

Nuclear Power Leading the Way

+15% Nuclear Power end-market orders growth, excluding M&A

Paragon is a leading indicator of the U.S. nuclear power momentum

Delivering on Large Opportunity Orders

~$50M of large opportunities awarded in Q1; $35M SMR order won in April

Remaining pipeline still intact; no potential orders lost

Year-over-year growth numbers reflect comparison vs. Q1'25
1 Excludes the July 2025 Certrec and December 2025 Paragon acquisitions.
2 Part of the 2025 large opportunity order pipeline previously disclosed.

Global Demand for Nuclear Power is Surging

Latest Data Points in Support of Nuclear Power

D.O.E. UPRISE INITIATIVE

~3–5 GW[1]

New U.S. initiative aims to increase nuclear power output through existing reactor uprates and restarts

+

GEOPOLITICAL UNCERTAINTY

~5–10 GW[2]

Oil & energy shock drives incremental nuclear power plans in hard-hit countries

=

~8–15 GW

(potential)

Estimated Net Incremental Nuclear Power Generation

Additional generation is required to meet new demand

U.S. UTILITY INVESTMENT

~$1.4T[3]

Projected U.S. electric utility investment from 2025 to 2030 to meet accelerating electrical demand

1 US Department of Energy (DoE); includes uprates, restarts, and completed stalled projects under DoE's UPRISE initiative
2 Yahoo News & Associated Press
3 PowerLines 2026 report: Utility Spending is Rising

Paragon Integration Progressing Well

Paragon Represents the 'Tip of the Spear' for Growing Installed Base Nuclear Power Momentum

Financial Performance[1]

Better than expected financial performance

+45% Paragon Revenue growth
Q1'26 vs. Q1'25

+206% Paragon Adj. EBITDA growth
Margin expansion vs. Q1'25

Integration Progress

Synergy on-plan; with upside opportunity

- Significant progress across both functional and commercial workstreams
- Identified additional synergy opportunities

Near-term Priorities

Prioritizing the customer experience

Installed Base | New Nuclear | SMR | Labs/DoE

- *Expanded joint customer engagement across strategic accounts and customer types*
- *Increased collaboration aligning customer coverage and identifying strongest areas for combined value creation*

1 Financial performance reflects unaudited condensed consolidated financial statements

Expanding Backlog Reflects Orders Momentum

Precursor to Accelerated Revenue Growth



Favorable Backlog Trend

Strong backlog provides high degree of visibility

Nuclear Power Dominated

62% of backlog related to the Nuclear Power end-market

Further Expansion Expected

Large opportunity awards will further grow the pipeline

Backlog figures on an as reported basis. Total backlog figures include acquisitions of Oncospace, Certrec, and Paragon Energy Solutions. Q3'25 has been updated to include an additional $8M of Certrec orders compared to the previous reported amount to align the acquisition to the Company's backlog reporting policy.

Medical Segment Update

Rebounding RTQA; On-track More Broadly

RTQA[1]
~50% of '25A segment revenue

- Improving U.S. orders, including large camera order *(~$20 million order)*
- Green shoots in Q1'26 hardware demand; software remains a bright spot

Nuclear Medicine
~25% of '25A segment revenue

- On-track for double-digit organic revenue growth
- Expanding international reach

Dosimetry
~25% of '25A segment revenue

- Stable business with strong recurring revenue
- Driving cross-sell opportunities within the Nuclear & Safety segment

1 Radiation Therapy Quality Assurance

Q1 Performance Highlights

$257.6M
Q1'26 Revenue

+3.0% organic vs. Q1'25; +27.5% total; highlights demand from the Nuclear Power and RTQA end-markets

$54.3M
Q1'26 adj. EBITDA

+16.3% vs. Q1'25; (200bps) margin contraction primarily due to margin-dilutive M&A, one-timers in the prior year, and mix – as expected

$16M
shares repurchased value in Q1'26

0.7 million shares repurchased in Q1'26; offsetting stock compensation dilution

$11M Q1 Adj. FCF Generation

Net working capital timing impacting Q1 performance

Strong Q1 Orders

+19% vs. Q1'25; excluding M&A. +42% including M&A. Orders growth across both operating segments

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.

Q1’26 Orders Performance

Delivering on the Large Opportunity Pipeline



KEY TAKEAWAYS:

1st Quarter 2026

Nuclear & Safety growth driven by continued **strong Nuclear Power performance**

Reflects ~$20M large new products cameras order from our RTQA end-market

Sizeable quarterly orders for Paragon; ~$35 million large SMR opportunity order already awarded in Q2’26

Orders figures on an ” basis.
1 Paragon acquisition closed in December 2025. This is the first full quarter of Paragon being included in Mirion’s financial and operational results.

2026 Large Opportunity Pipeline

~$350 Million of Incremental Opportunity Still Available

Small Modular Reactors	Radioactive Waste Handling	Operating Fleet Reactors	Radiation-hardened Cameras	Small Modular Reactors
		Paragon		Paragon
Partial order; more to come	*Partial order; more to come*	*Safety-critical qualification*	*RTQA Medical Segment order*	*Partial order; more to come*
Part of the remaining 2025 pipeline	*Part of the remaining 2025 pipeline*	*Incremental to original 2026 pipeline*	*Incremental to original 2026 pipeline*	*Part of the original 2026 pipeline*

***~$50M** of large opportunities awarded in Q1*

***~$35M** Q2 award*

16 Large opportunity pipeline in-queue

9 *New build opportunities*
Includes large-scale nuclear power plants (all non-U.S.) & SMRs[1]

2 *Installed base opportunities*

5 *Other opportunities*

Large opportunity pipeline projects are $10 million or more.
1 NPP = large-scale nuclear power plants; SMR = small modular reactor.

Stacking Nuclear Power Wins

Remain Confident in our Double-digit Organic Revenue Growth Projection

Nuclear Power End-market

+15%

Orders excl. M&A[1]

Q1'26 vs. Q1'25

+9% excluding FX

$15M

SMR-related Orders

+$13M Q1'26 vs. Q1'25

$35M Paragon SMR partial award in April

+4%

+18% Q1'25 — *Continued growth in '26 against a difficult year-over-year comparable*

Adjusted Revenue[1]

Q1'26 vs. Q1'25

flat organic revenue

1 Excludes the July 2025 Certrec and December 2025 Paragon acquisition.

Mirion

First Quarter Ended March 31, 2026

Revenue

$ millions | % percentage

%	Q1'26 vs. Q1'25
Organic	*+3.0%*
Acquisition	*+21.0%*
FX	*+3.5%*
Total	***+27.5%***



Adjusted EBITDA and Margin

$ millions | % percentage



Adjusted EBITDA Margin: *23.1%* (Q1'25) | *21.1%* (Q1'26)

Adjusted diluted EPS[1]

$ cents



For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q1 2025 and Q1 2026 are to the three months ended March 31, 2025 and 2026, respectively.
Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.
1 Q1'26 is the initial quarter that we are including stock-based compensation in the Adjusted EPS calculation. Note, Q1'25 is excluding stock-based compensation.

Mirion Nuclear & Safety

First Quarter Ended March 31, 2026

Revenue

$ millions | % percentage

%	Q1'26 vs. Q1'25
Organic	*+2.6%*
Acquisition	*+31.6%*
FX	*+4.9%*
Total	***+39.1%***



Adjusted EBITDA and Margin

$ millions | % percentage



Adjusted EBITDA Margin:	*29.4%*	*25.2%*

KEY TAKEAWAYS:

1st Quarter 2026

- Includes a full quarter's benefit of **Paragon and accelerating SMR revenue**
- **+31% growth in Defense and Diversifieds end-market revenue** primarily related to NATO & U.S. military & civil
- **Adj. EBITDA margin decrease** driven by dilutive impacts from M&A *~(200bps)* and mix-related impacts *~(200bps)*; comping a +300bps margin improvement in Q1'25

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q1 2025 and Q1 2026 are to the three months ended March 31, 2025 and 2026, respectively.
Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.

Mirion Medical

First Quarter Ended March 31, 2026

Revenue

$ millions | % percentage

%	Q1'26 vs. Q1'25
Organic	*+3.8%*
Acquisition	*+0.2%*
FX	*+1.1%*
Total	***+5.1%***



Adjusted EBITDA and Margin

$ millions | % percentage



Adjusted EBITDA Margin: Q1'25: *33.8%* | Q1'26: *34.1%*

KEY TAKEAWAYS:

1st Quarter 2026

- **Double Digit RTQA organic revenue growth** driven by the rebound from '25 ERP implementation; RTQA software and cameras
- Lower Q1 Dosimetry end-market organic revenue driven by **tough hardware comparable** in Q1'25
- **Expanding margin performance** from operating leverage and price; tough comp vs. Q1'25 margin growth of +310bps

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q1 2025 and Q1 2026 are to the three months ended March 31, 2025 and 2026, respectively.
Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.

Adjusted Free Cash Flow

Project Timing Impacting Q1’26 Adjusted Free Cash Flow

Adjusted Free Cash Flow & Conversion

$ millions | % adj. EBITDA percentage



Q1 NET WORKING CAPITAL IMPACT

Use of cash in the quarter *(vs. source of cash in Q1’25)*, primarily due to large nuclear projects timing

CAPITAL STRUCTURE IMPROVEMENTS

Full quarter’s impact reflected from capital structure improvements implemented in 2025

ON-TRACK FOR 2026 ADJUSTED FCF GUIDE

Q1 marks the trough

For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q1 2025 and Q1 2026 are to the three months ended March 31, 2025 and 2026, respectively.
Adjusted Free Cash Flow conversion is calculated as Adjusted Free Cash Flow divided by Adjusted EBITDA.

‘26 Guidance Reflects Strong Fundamentals

Growing Revenue, Expanding Margins, Increasing Adjusted Free Cash Flow Expected

FY 2026 Guidance[1]

TOTAL REVENUE GROWTH

~22.0 – 24.0%

Includes FX and acquisition-related tailwinds

ORGANIC REVENUE GROWTH[2]

~5.0 – 7.0%

ADJUSTED EBITDA
Margin %

~$285 – $300M
~25.0% – 26.0%

UPDATED

ADJUSTED FCF
Adjusted FCF Conversion
% of Adjusted EBITDA

~$155 – $175M
54% – 58%

ADJUSTED EARNINGS PER SHARE[2]

~$0.48 – $0.55
per share

Modified to reflect the impact of a special one-time CEO retention grant of performance vesting stock options[4]

ANNUALIZED FOREIGN EXCHANGE SENSITIVITY[3]

+/- $3.5M
Revenue for every .01 Δ

+/- $1M
Adjusted EBITDA for every .01 Δ

1 2026 guidance includes an assumed fourth quarter 2025 foreign exchange rate of 1.175 Euro-to-USD,
2 Includes interest expense savings from convertible notes and refinanced Term Loan B; interest income from incremental cash on the balance sheet; additional earnings from acquisitions; stock-based compensation.
3 Foreign exchange sensitivities are based on Euro exchange rates.
4 Revised Adjusted EPS guidance to reflect the impact of a special one-time CEO grant of performance vesting stock options disclosed on April 13, 2026.

Appendix

Organic Growth

Performance and Trends

MIRION

5.0 – 7.0%

'26E ORGANIC REVENUE GROWTH

Driven by Nuclear Power

NUCLEAR & SAFETY

END MARKET	NUCLEAR & SAFETY	NUCLEAR POWER	LABS & RESEARCH	DEFENSE & DIVERSIFIED INDUSTRIALS
2025 Organic Growth	MSD	DD	Neg HSD	LSD
2026E Organic Growth	HSD	DD	FLAT	MSD
2025 & 2026E COMMENTARY & TRENDS		• **2025:** New build and installed base driving double-digit growth; SMR accelerating • **2026E:** SMR expected to be a bigger contributing factor; new build & installed base should demonstrate continued growth	• **2025:** Negatively impacted by **(1)** delayed U.S. DoE and Chinese demand; **(2)** government shutdown; **(3)** and DOGE impacts. • **2026E:** Activity improving in Q1 but government spend and timing remains uncertain	• **2025:** Double-digit industrials growth partially offset by a tough comparable of European civil defense revenue in 2024 • **2026E:** Accelerated defense revenue expected; tough comparable in diversified industrials

MEDICAL

END MARKET	MEDICAL	RADIATION THERAPY QUALITY ASSURANCE (RTQA)	NUCLEAR MEDICINE	DOSIMETRY
2025 Organic Growth	LSD	Neg	DD	LSD
2026E Organic Growth	MSD	MSD+	DD	FLAT
2025 & 2026E COMMENTARY & TRENDS		• **2025:** Hardware headwinds in N. America, China, and Japan; partially offset by software tailwinds • **2026E:** Growing software platform in the U.S. and RoW; hardware market stabilizing	• **2025:** Hardware growth in the U.S. and RoW supported by expansion of clinic growth • **2026E:** Continued hardware growth enhanced with software offerings	• **2025:** Continued adoption of InstadoseVUE®; timing headwind earlier in 2025 • **2026E:** Progress expected from InstadoseVUE®; identifying additional markets to address; difficult hardware comp from 2025

CANCER CARE

Non-GAAP Reconciliations

Adjusted Free Cash Flow and Net Leverage

($ millions)	Q1 2023	Q1 2024	Q1 2025	Q1 2026
Net cash provided by operating activities	**$(2.7)**	**$6.0**	**$35.6**	**$18.9**
Purchases of PPE and badges	(7.5)	(12.8)	(8.5)	(9.5)
Proceeds from derivative contracts	–	1.2	1.0	0.6
Cash used for non-operating expenses	3.0	1.1	0.7	1.3
Adjusted Free Cash Flow	**$(7.2)**	**$(4.5)**	**$28.8**	**$11.3**
Ending cash balance	$88	$120	$186	$398
Debt from first lien term loan	697	695	695	450
Convertible Notes	–	–	–	775
Net Debt	**$609**	**$575**	**$509**	**$827**
LTM Adjusted EBITDA	166	184	211	236
LTM Adjusted EBITDA Contribution from M&A *(proforma)*	2	3	0	17
LTM Adjusted EBITDA Plus M&A Contribution	**$168**	**$187**	**$211**	**$253**
Total Net Debt / M&A Adjusted EBITDA (Net Leverage)	**3.6x**	**3.1x**	**2.4x**	**3.3x**

- **Working Capital:** Use of cash reflects large nuclear project cash timing.
- **Net Interest Expense:** Reflects **(1)** reduced interest expense from lower Term Loan B principal partially offset by two convertible notes; and **(2)** higher interest income from elevated cash held from October 2025 capital raise to fund the December 2025 acquisition of Paragon.
- **Net Leverage:** <2.5x expected by year-end[1]; in-line with our long-term net leverage target.

1 Assuming no M&A activity or capital raises.

Modeling Assumptions

Supporting 2026 Guidance

Amortization: *(pre any incremental M&A)*
~$118M; *includes ~$25M associated with Paragon*

Interest Expense:
$450M SOFR + 2.00% for the '32 Term Loan B;
$400M 0.25% '30 convert notes; **$375M** 0% '31 convert notes

Capex:
~$60M

Net Working Capital:
use of cash; *productivity metrics improving; more than offset by project timing*

Cash Taxes:
~$35M

Stock-based Compensation:
~$26M

Effective Tax Rate:
~25 - 27%

Foreign Exchange Rate *(EUR-to-USD)***:**
1.175

Basic Share Count:
~246M shares

Diluted Share Count:
~275M shares; *includes convertible notes and equity raise*

Nine Quarter Segment Reconciliation

Nuclear & Safety

($ in millions)	1Q 2026	4Q 2025	3Q 2025	2Q 2025	1Q 2025	4Q 2024	3Q 2024	2Q 2024	1Q 2024
Revenue	**$ 185.5**	**$ 194.9**	**$ 144.6**	**$ 141.7**	**$ 133.4**	**$ 168.8**	**$ 132.7**	**$ 133.9**	**$ 125.8**
YoY % Growth - Total	*39.1 %*	*15.5 %*	*9.0 %*	*5.8 %*	*6.0 %*	*13.2 %*	*8.4 %*	*3.7 %*	*8.7 %*
YoY % Growth - Organic	*2.6 %*	*3.1 %*	*4.4 %*	*2.9 %*	*7.6 %*	*13.9 %*	*7.8 %*	*4.1 %*	*8.4 %*
YoY % Growth - Acquisitions	*31.6 %*	*7.6 %*	*1.8 %*	*— %*	*— %*	*— %*	*— %*	*— %*	*— %*
YoY % Growth - FX	*4.9 %*	*4.8 %*	*2.8 %*	*2.9 %*	*(1.6)%*	*(0.7)%*	*0.6 %*	*(0.4)%*	*0.3 %*
Income (Loss) from Operations	**$ 20.9**	**$ 39.1**	**$ 21.3**	**$ 19.0**	**$ 21.7**	**$ 33.1**	**$ 14.7**	**$ 18.5**	**$ 12.6**
Amortization	19.6	15.4	14.3	13.7	13.7	13.7	17.1	17.3	17.8
Depreciation	4.7	4.0	3.6	3.6	3.3	3.5	2.5	2.4	2.4
Stock compensation	0.7	0.9	0.7	0.3	0.5	0.5	0.5	0.4	0.4
Cost of revenues impact from inventory valuation purchase accounting	0.8	—	—	—	—	—	—	—	—
Non-operating expenses	0.1	0.4	0.7	1.0	—	1.7	—	0.4	—
Other income/expense	—	0.2	—	0.3	—	0.3	0.1	(0.1)	(0.1)
Adjusted EBITDA	**$ 46.8**	**$ 60.0**	**$ 40.6**	**$ 37.9**	**$ 39.2**	**$ 52.8**	**$ 34.9**	**$ 38.9**	**$ 33.1**
Income from operations margin	*11.3 %*	*20.1 %*	*14.7 %*	*13.4 %*	*16.3 %*	*19.6 %*	*11.1 %*	*13.8 %*	*10.0 %*
Adjusted EBITDA margin	*25.2 %*	*30.8 %*	*28.1 %*	*26.7 %*	*29.4 %*	*31.3 %*	*26.3 %*	*29.1 %*	*26.3 %*

Nine Quarter Segment Reconciliation

Medical

($ in millions)	1Q 2026	4Q 2025	3Q 2025	2Q 2025	1Q 2025	4Q 2024	3Q 2024	2Q 2024	1Q 2024
Revenue	**$ 72.1**	**$ 82.5**	**$ 78.5**	**$ 81.2**	**$ 68.6**	**$ 85.5**	**$ 74.1**	**$ 73.2**	**$ 66.8**
YoY % Growth - Total	*5.1 %*	*(3.5)%*	*5.9 %*	*10.9 %*	*2.7 %*	*5.2 %*	*7.7 %*	*7.7 %*	*0.6 %*
YoY % Growth - Organic	*3.8 %*	*(4.8)%*	*5.2 %*	*10.1 %*	*3.0 %*	*3.7 %*	*3.2 %*	*2.6 %*	*0.6 %*
YoY % Growth - Acquisitions	*0.2 %*	*0.4 %*	*0.1 %*	*0.2 %*	*— %*	*1.5 %*	*4.4 %*	*5.2 %*	*(0.1)%*
YoY % Growth - FX	*1.1 %*	*0.9 %*	*0.6 %*	*0.6 %*	*(0.3)%*	*— %*	*0.1 %*	*(0.1)%*	*0.1 %*
Income (Loss) from Operations	**$ 7.8**	**$ 18.6**	**$ 10.7**	**$ 10.9**	**$ 6.7**	**$ 11.9**	**$ 4.0**	**$ 5.0**	**$ 1.4**
Amortization	11.4	10.7	11.4	11.5	11.7	12.2	13.0	13.7	13.7
Depreciation	4.8	5.4	5.3	4.8	4.7	5.1	5.5	4.9	4.8
Stock compensation	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2
Non-operating expenses	—	(0.1)	0.6	2.6	—	3.8	2.4	1.4	0.4
Other income/expense	—	(0.2)	(0.3)	(0.1)	(0.3)	(0.1)	0.5	(0.2)	—
Adjusted EBITDA	**$ 24.6**	**$ 34.9**	**$ 28.2**	**$ 30.1**	**$ 23.2**	**$ 33.2**	**$ 25.7**	**$ 25.1**	**$ 20.5**
Income from operations margin	*10.8 %*	*22.5 %*	*13.6 %*	*13.4 %*	*9.8 %*	*13.9 %*	*5.4 %*	*6.8 %*	*2.0 %*
Adjusted EBITDA margin	*34.1 %*	*42.3 %*	*35.9 %*	*37.1 %*	*33.8 %*	*38.8 %*	*34.7 %*	*34.3 %*	*30.7 %*

Nine Quarter Segment Reconciliation

Corporate & Other

($ in millions)	1Q 2026	4Q 2025	3Q 2025	2Q 2025	1Q 2025	4Q 2024	3Q 2024	2Q 2024	1Q 2024
Revenue	**$ —**	**$ —**	**$ —**	**$ —**	**$ —**	**$ —**	**$ —**	**$ —**	**$ —**
Income (Loss) from Operations	**$ (25.0)**	**$ (32.2)**	**$ (24.6)**	**$ (20.0)**	**$ (19.7)**	**$ (16.0)**	**$ (20.3)**	**$ (21.2)**	**$ (18.9)**
Amortization	—	—	—	—	—	—	—	—	—
Depreciation	0.3	0.1	0.2	0.3	0.3	0.1	0.4	0.2	0.1
Stock compensation	3.0	2.6	3.2	2.7	2.5	2.9	3.5	3.3	3.0
Non-operating expenses	4.8	12.1	4.1	0.4	1.2	(3.7)	1.7	2.5	1.7
Other income/expense	(0.2)	0.1	0.7	(0.2)	—	0.3	(0.2)	—	—
Adjusted EBITDA	**$ (17.1)**	**$ (17.3)**	**$ (16.4)**	**$ (16.8)**	**$ (15.7)**	**$ (16.4)**	**$ (14.9)**	**$ (15.2)**	**$ (14.1)**
Income from operations margin	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*	*n.a*
Adjusted EBITDA margin	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*	*n.a.*

Nine Quarter Segment Reconciliation

Consolidated

($ in millions)	1Q 2026	4Q 2025	3Q 2025	2Q 2025	1Q 2025	4Q 2024	3Q 2024	2Q 2024	1Q 2024
Revenue	**$ 257.6**	**$ 277.4**	**$ 223.1**	**$ 222.9**	**$ 202.0**	**$ 254.3**	**$ 206.8**	**$ 207.1**	**$ 192.6**
YoY % Growth - Total	*27.5 %*	*9.1 %*	*7.9 %*	*7.6 %*	*4.9 %*	*10.4 %*	*8.2 %*	*5.0 %*	*5.8 %*
YoY % Growth - Organic	*3.0 %*	*0.5 %*	*4.7 %*	*5.4 %*	*6.0 %*	*10.3 %*	*6.1 %*	*3.6 %*	*5.5 %*
YoY % Growth - Acquisitions	*21.0 %*	*5.2 %*	*1.1 %*	*0.1 %*	*— %*	*0.5 %*	*1.6 %*	*1.8 %*	*— %*
YoY % Growth - FX	*3.5 %*	*3.4 %*	*2.1 %*	*2.1 %*	*(1.1)%*	*(0.4)%*	*0.5 %*	*(0.4)%*	*0.3 %*
Income (Loss) from Operations	**$ 3.7**	**$ 25.5**	**$ 7.4**	**$ 9.9**	**$ 8.7**	**$ 29.0**	**$ (1.6)**	**$ 2.3**	**$ (4.9)**
Amortization	31.0	26.1	25.7	25.2	25.4	25.9	30.1	31.0	31.5
Depreciation	9.8	9.5	9.1	8.7	8.3	8.7	8.4	7.5	7.3
Stock compensation	4.3	4.0	4.4	3.4	3.4	3.7	4.3	4.0	3.6
Cost of revenues impact from inventory valuation purchase accounting	0.8	—	—	—	—	—	—	—	—
Non-operating expenses	4.9	12.4	5.4	4.0	1.2	1.8	4.1	4.3	2.1
Other income/expense	(0.2)	0.1	0.4	—	(0.3)	0.5	0.4	(0.3)	(0.1)
Adjusted EBITDA	**$ 54.3**	**$ 77.6**	**$ 52.4**	**$ 51.2**	**$ 46.7**	**$ 69.6**	**$ 45.7**	**$ 48.8**	**$ 39.5**
Income from operations margin	*1.4 %*	*9.2 %*	*3.3 %*	*4.4 %*	*4.3 %*	*11.4 %*	*(0.8)%*	*1.1 %*	*(2.5)%*
Adjusted EBITDA margin	*21.1 %*	*28.0 %*	*23.5 %*	*23.0 %*	*23.1 %*	*27.4 %*	*22.1 %*	*23.6 %*	*20.5 %*

Non-GAAP Reconciliations

Consolidated – Income from Operations, Gross Profit & Adjusted EBITDA

($ in millions)	Three Months Ended March 31, 2026		Three Months Ended March 31, 2025	
GAAP Net (Loss) Income	**$**	**(3.4)**	**$**	**0.4**
Interest expense, net		5.0		10.6
Income tax (benefit) expense provision		(1.8)		0.2
Foreign currency loss (gain), net		3.7		(2.8)
Other income/expense		0.2		0.3
Income from Operations	**$**	**3.7**	**$**	**8.7**
Amortization	$	31.0	$	25.4
Depreciation		9.8		8.3
Stock compensation expense		4.3		3.4
Cost of revenues impact from inventory valuation purchase accounting		0.8		—
Non-operating expenses		4.9		1.2
Other income/expense		(0.2)		(0.3)
Adjusted EBITDA	**$**	**54.3**	**$**	**46.7**

Gross Profit	**$**	**119.1**	**$**	**96.1**
Amortization		6.9		6.8
Depreciation		5.8		5.5
Cost of revenues impact from inventory valuation purchase accounting		0.8		—
Non-operating expenses		0.1		—
Adjusted Gross Profit	**$**	**132.7**	**$**	**108.4**
Adjusted Gross Profit margin		*51.5 %*		*53.7 %*

Non-GAAP Reconciliations

Adjusted Earnings per Share

($ in millions)		Three Months Ended March 31, 2026		Three Months Ended March 31, 2025
Net (loss) income attributable to Mirion Technologies, Inc. stockholders	$	(3.4)	$	0.3
Income attributable to noncontrolling interests		—		0.1
GAAP net (loss) income		(3.4)		0.4
Foreign currency loss (gain), net		3.7		(2.8)
Amortization of acquired intangibles		31.0		25.4
Stock-based compensation[1]		—		3.4
Cost of revenues impact from inventory valuation purchase accounting		0.8		—
Non-operating expenses		4.9		1.2
Tax impact of adjustments above		(10.3)		(5.2)
Adjusted net income	$	26.7	$	22.4
Weighted average common shares outstanding — basic and diluted		244.663		225.655
Dilutive potential common shares - stock-based awards		0.589		1.263
Dilutive potential common shares - convertible debt		30.321		0.000
Adjusted weighted average common shares — diluted		275.573		226.918
Net loss per common share attributable to Mirion Technologies, Inc.	$	(0.01)	$	—
Adjusted EPS	$	0.10	$	0.10
Convertible Notes		30.321		n.a.
Convertible notes impact on adjusted EPS	$	0.012		n.a.
Public Offering		19.906		n.a.
Public offering impact on adjusted EPS	$	0.010		n.a.
Adjusted EPS excluding convertible notes & public offering	$	0.12		n.a.

1 The calculation for adjusted net income has been adjusted for the current period to include stock-based compensation.

Share Count

Details[1]

Share Description	Outstanding Securities as of 3/31/2026[2]	Outstanding Securities as of 12/31/2025[2]	Notes
Shares of Class A Common Stock, including Treasury Stock	**248,772,252**	**248,155,411**	▪ **Shares as of close of trading on the New York Stock Exchange (NYSE), including treasury stock purchased by Mirion**
Treasury Stock	(4,376,586)	(3,492,619)	▪ During the three months ended March 31, 2026, Mirion purchased 0.7 million shares of Class A common stock as part of a share repurchase program.
Outstanding Shares of Class A Common Stock	**244,395,666**	**244,662,792**	▪ **Outstanding shares as of close of trading on the New York Stock Exchange (NYSE), excluding treasury stock**
Shares of Class B Common Stock – Mirion Management[3]	5,864,555	5,869,555	▪ Shares of Class B common stock are owned by certain current and former members of Mirion's management team and are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co, Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one-basis or cash based on a trailing stock price average.
Illustrative Total Shares Outstanding	**250,260,221**	**250,532,347**	
Convertible Notes	30,320,703	30,320,703	▪ During the year ended December 31, 2025, Mirion issued $775 million of notes potentially convertible to shares of Class A common stock (subject to the terms of the notes). The dilutive impact shown is based upon an initial conversion rate of 43.2751 shares per $1,000 principal amount of the May issuance ($400 million) and 34.6951 shares per $1,000 principal amount of the September issuance ($375 million).
Outstanding Equity Awards[4]	3,124,245	2,424,049	▪ Mirion had 1.1 million shares of restricted stock units and 2.0 million shares of performance stock units outstanding as of March 31, 2026. Additionally, Mirion had reserved an additional 45.8 million shares of Class A common stock for future equity awards issuance under its 2021 Omnibus Incentive Plan (subject to annual automatic increases) as of March 31, 2026.
Total Illustrative Fully Diluted Shares	**283,705,169**	**283,277,099**	

1 All data on this slide is as of March 31, 2026, or December 31, 2025, unless otherwise noted. All share numbers and dollar amounts are subject to adjustment for stock splits or other similar events.

2 This slide illustrates Mirion's outstanding and fully diluted shares based on certain assumptions set forth in the "Notes" column and is designed to be illustrative and provide investors with additional information only. Different assumptions will yield different results, and the actual number of our fully diluted shares in the future may differ significantly from those based on these assumptions. As a result, you should not rely on these forward-looking statements as predictions of future events. The information provided is not presented in accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share (ASC 260) and does not represent a computation of weighted average shares nor are the numbers appropriate for calculating Basic or Diluted EPS under ASC 260.

3 The slide illustrates the assumption that all of the paired interests will be redeemed and exchanged for shares of Class A common stock.

4 The number of reserved shares are subject to automatic increases on the first day of each year in an amount equal to the lesser of (i) three percent (3%) of the outstanding shares of Class A common stock on the last day of the immediately preceding year, (ii) 9,976,164 shares of Class A common stock and (iii) such number of shares of Class A common stock as determined by Mirion Compensation Committee in its discretion.

Convertible Notes (Issued May and September 2025)

Illustrative Table of Potential Dilutive Impact of Convertible Notes due 2030 & 2031 and Capped Call Overlay

Following table illustrates the potential dilutive shares under (i) our $400M aggregate principal amount of convertible notes due 2030 and (ii) our $375M aggregate principal amount of convertible notes due 2031 (together, "the Notes") that would be included in the calculation of our future reported GAAP EPS assuming various hypothetical quarterly average market prices of our common stock (NYSE: MIR). The capped calls on each of the Notes are not included in the calculation of diluted GAAP EPS as they are anti-dilutive. The Notes are expected to have a dilutive effect on GAAP EPS while outstanding, but the actual dilution at maturity is reduced by the effects of our capped calls and upon an irrevocable election to net share settle the Notes

	GAAP EPS Impact[2]	Actual Dilution Impact[3]		
Hypothetical Quarterly Average Share Price[1]	**Total Underlying Shares from Notes**	**Net Shares from the Notes**	**Net Shares Received from the Capped Calls**	**Total Expected Dilution at Maturity of the Notes**
$15.00	30.32	-	-	-
$17.50	30.32	-	-	-
$20.00	30.32	-	-	-
$22.50	30.32	-	-	-
$25.00	30.32	1.31	(1.31)	-
$27.50	30.32	2.76	(2.76)	-
$30.00	30.32	4.49	(4.49)	-
$32.50	30.32	6.47	(6.47)	-
$35.00	30.32	8.18	(8.12)	0.06
$40.00	30.32	10.95	(8.73)	2.22
$45.00	30.32	13.10	(8.54)	4.56
$50.00	30.32	14.82	(7.69)	7.13
$55.00	30.32	16.23	(6.99)	9.24
$60.00	30.32	17.40	(6.41)	11.00

Note: This table is for illustrative purposes and does not represent our forecast of future stock performance
1 The prices listed in the table are illustrative. Although dilution continues beyond $60 per share, we have not presented further data
2 Assumes if-converted accounting, excludes offset of capped call (non-GAAP metric)
3 Assumes intent to net share settle convertible notes (treasury stock method accounting); includes offset of capped call (non-GAAP metric)

Footnotes

Share Count and Adjusted Metrics

Share count

244,395,666 shares of Class A common stock were outstanding as of March 31, 2026. This excludes (1) 5,864,555 shares of Class B common stock outstanding as of March 31, 2026; (2) 1,068,248 shares of Class A common stock underlying restricted stock units and 2,055,997 shares of Class A common stock underlying performance stock units; and (3) any other shares issuable from future equity awards under our 2021 Omnibus Incentive Plan, which had 45,800,089 shares reserved (subject to annual automatic increases) as of March 31, 2026. The 5,864,555 shares of Class B common stock are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co., Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one basis or cash based on a trailing stock price average. All share data is as of March 31, 2026, unless otherwise noted.

Reconciliation of Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Organic revenues is defined as revenues excluding the impact of foreign exchange rates as well as mergers, acquisitions and divestitures in the period.

Adjusted gross profit is defined as gross profit adjusted to exclude the impact of amortization of acquired intangible assets, depreciation, the impact of purchase accounting on the recognition of deferred revenue and certain non-operating expenses (certain purchase accounting impacts related to inventory and costs to achieve operational synergies).

Adjusted EBITDA is defined as net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the impact of foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.

Adjusted net income is defined as GAAP net income adjusted for foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.

Adjusted EPS is as adjusted net (loss) income divided by weighted average common shares outstanding — basic and diluted.

Adjusted free cash flow is defined as free cash flow adjusted to include the impact of cash used to fund non-operating expenses described above. We believe that the inclusion of supplementary adjustments to free cash flow applied in presenting adjusted free cash flow is appropriate to provide additional information to investors about our cash flows that management utilizes on an ongoing basis to assess our ability to generate cash for use in acquisitions and other investing and financing activities.

Adjusted free cash flow conversion is defined as adjusted free cash flow divided by adjusted EBITDA.

Free cash flow is defined as U.S. GAAP net cash provided by operating activities adjusted to include the impact of purchases of property, plant, and equipment, purchases of badges and proceeds from derivative contracts.

Net leverage is defined as net debt (debt minus cash and cash equivalents) divided by Adjusted EBITDA plus contributions to Adjusted EBITDA if acquisitions made during the applicable period had been made before the start of the applicable period.

Operating Metrics

Orders and Order growth are defined as the amount of revenue earned in a given period and estimated to be earned in future periods from contracts entered into in a given period as compared with such amount for a prior period. Foreign exchange rates are based on the applicable rates for the time period.

MIRION